MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Diabetic kidney disease

  • Home
  • Diabetic kidney disease
SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation

Posted by By MedXY 01/26/2026
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
Read More
PAD4, NETs, and Inflammasome Activation: A New Mechanistic Link Between Diabetes and Cardiorenal Injury
Posted inCardiology Nephrology news

PAD4, NETs, and Inflammasome Activation: A New Mechanistic Link Between Diabetes and Cardiorenal Injury

Posted by By MedXY 11/28/2025
A translational study links hyperglycaemia-driven PAD4-dependent neutrophil extracellular trap (NET) formation and inflammasome activation to cardiac and renal inflammation, fibrosis, and heart failure in experimental diabetes—suggesting novel therapeutic targets.
Read More
  • Enhancing Inter-Visit Care in Internal Medicine Residency: Integrating Structural Support and Educational Curriculum
  • Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes: A Comprehensive Review
  • Periconceptional Vitamin B12 and Folate Levels in Parents Linked to Birth Defect Risk Reduction: Insights from a Large Prospective Cohort
  • TP53 Mutations in Acute Myeloid Leukemia: Impact on Outcomes Post-Allogeneic Hematopoietic Cell Transplantation
  • Pre-Transplant KMT2A-PTD Measurable Residual Disease as a Prognostic Biomarker in Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top